Be part of research

What is maternity research?

At Royal Cornwall Hospitals, we carry out research to gather evidence on what works in maternity services so that we can deliver the best possible care for women, children and their families – now and in the future.

Clinical research is, and always has been, at the very heart of the NHS. Only by carrying out research into “what works” can we continually improve drugs, treatments and care pathways for patients, and understand how to focus NHS resources where they will be most effective.

There is also evidence that shows that just being in a research study can improve a persons’ outcomes, and sometimes being in a study can give access to treatments that otherwise might not be available for a few years.

Find out more about clinical trials in the ‘Understanding clinical trials’ leaflet produced by NHS National Institute for Health Research.

What we are all about

Our dedicated team of research Drs, midwives, nurses and research support staff understand the importance of evidence-based practice and are well placed to recognise opportunities for improvement in patient care.

We are working closely with Cornwall’s Research and Innovation team and the NIHR Clinical Research Network for the Southwest, who fund the research midwife posts at Cornwall’s Hospital.

Working collaboratively with the wider research team here at RCHT, the midwifery research team recruit to midwifery, obstetric and neonatal research studies to add to our body of knowledge and improve patient care across the county.

This site will introduce you to our maternity, obstetric and neonatal studies, but as a team we also support wider paediatric and gynaecological studies not detailed here. If you are interested in taking part in any of these studies, then please contact the Kensey Research Team here at the Royal Cornwall Hospital and we can have a chat about which studies are appropriate for you.

So, why is research important?

Research means we can:

  • develop new and better treatments
  • be better at preventing problems and making a quick diagnosis
  • give you the best care

We want to ensure that the care of future generations of mothers and babies is even better than the care we give now. The way we can do this is by participating in research trials and studies and you are a key part of helping us do this.

Research can only happen with your help. Please join us!

Contact us

Department of Research and Development
Kensey Team
Level 1 KSPA F37
Royal Cornwall Hospital
Treliske
Truro
TR1 5HD

Current Trials

Studies may run for many years and other studies may only be open to recruitment for a few months. 

Here we describe  the studies that are currently open to recruitment in our maternity and newborn and neonatal departments  at Royal Cornwall Hospitals. There are studies coming through all the time, so please contact us for more information and details of what we are looking forward to.

In line with the principles of Good Clinical Practice in research, participation in any research study is always voluntary and if you take part in a study but then later change your mind, you can withdraw from the study at any time without giving a reason and without your care being affected in any way.

We look forward to hearing from you.


The neoGASTRIC Study – Premature Baby Feeding (Neonatal)

neoGASTRIC logo

This neonatal unit is taking part in an important research study called neoGASTRIC which is comparing care practices that already take place in neonatal units across the United Kingdom (UK). We plan to include every eligible baby in the study unless you tell us you do not want your baby to take part (opt out).

Why?

Premature babies aren’t always able to suck and swallow their milk. That’s why they are fed milk every few hours through a soft tube which lies in their stomach. The tube is called a ‘gastric tube’ and is placed via the nose or mouth.

When a baby has a gastric tube in, some doctors and nurses routinely measure gastric residual volumes – checking to see how much milk is left in the baby’s stomach before the next feed. Some doctors and nurses routinely measure gastric residual volumes because they think it might help tell if the baby is coping with their feeds and may help identify signs of a serious but rare gut disease called necrotising enterocolitis (NEC). Other doctors and nurses think that routinely measuring gastric residual volumes may not be a good idea because it can be inaccurate, and we do not know if it does help to identify necrotising enterocolitis (NEC).

In the UK about half of doctors and nurses routinely measure gastric residual volumes and about half don’t – so both approaches are standard treatment. So, to check whether or not routinely measuring gastric residual volumes is safe or harmful we need to collect information on thousands of premature babies. The neoGASTRIC study will answer this question by comparing babies who have routine gastric measurements with those who do not to see if they can reach full feeds quicker without increasing their chance of getting necrotising enterocolitis (NEC).

Who is it for?

The neoGASTRIC study is for babies born more than 6 weeks early and needing a feeding tube.

To find out more:

If you are interested in taking part, please contact us

Research Midwives, Kensey Team


neonIN and neoAMRO Studies – Infection Surveillance in Babies (Neonatal)

Our Neonatal Unit is part of a network of neonatal units, which contribute information on infections to a central database (neonIN).

  • Neonatal Infection Surveillance Network: neonIN – trial recently extended
  • Neonatal Antimicrobial Resistance and Outcome: neoAMRO – trial recently closed to further recruitment

What?

These are both surveillance studies aiming to capture information about infections in newborn babies who are admitted to a neonatal unit that will help us improve the way we identify, treat, and manage infections in the future.

Infection in newborn babies is common yet until now there has been no detailed and on-going collection of information about infections in the UK. Such information can tell us which the most common infections are, what factors make these infections more likely and which antibiotics are best for treating them.

The database will allow this information to be gathered and analysed easily and ensure that the information is up to date.

What does it mean for my baby?

Unless you specifically object, basic information about your baby will be stored by one of your doctors on a database. They will use a code number; no names or addresses are attached to the results. Your child cannot be identified from the information kept on the database. If you would prefer that this does not happen, please tell your doctors. Declining to take part will not affect or alter any decisions about your baby’s care or treatment.

Who is it for?

Infants on neonatal units who have an episode of infection with a positive culture.

To find out more:

If you are interested in taking part, please contact us

Research Midwives, Kensey Team


Pioneer

Why?

PIONEER aims to investigate whether taking the medication Pravastatin reduces the number of babies born too early (preterm i.e., before 37 weeks of pregnancy), in pregnant people who are at medium to high risk of preterm birth. The trial also aims to understand how Pravastatin prevents preterm birth. 

What is involved?

With your permission, we would take a sample of blood from you at the start of the study to check if you are eligible to take part. If the results of the blood test show that you are eligible to take part and you would still like to take part in the study, you will be given either a placebo or Pravastatin. This will be decided by chance in a process we call randomisation. Neither the pregnant woman or the researchers will know which tablet they have been given until the end of the study. 

There will be two additional visits to hospital with an extra blood test at each. Transport and childcare costs will be offered to help make your study visits easier.  

Who is it for?

Anyone whose midwife has identified them as having a higher chance of having a pre-term birth. 

To find out more:

If you are interested in taking part, please contact us

Research Midwives, Kensey Team


Exploring Patterns in Pregnant Women’s Leisure Time Physical Activity LTPA 

Why? 

The research will provide us with a new understanding about the role of motivation and support from midwifery and consultant-led care in the relationship between fear of harm and leisure time physical activity levels across early, mid and late pregnancy.  

What’s involved? 

Participants will be asked to download an app on their phone and wear a wrist activity tracker (supplied) for one week during each trimester of their pregnancy. During this week they will receive prompts and be asked to answer quick questions throughout the day.  

Who’s it for? 

Anyone pregnant between 10 and 16 weeks. 

If you are interested in taking part, please contact us

Research Midwives, Kensey Team


Surfs Up (SURFactant Administration by SUPraglottic Airway) 

Why? 

Some babies will require treatment with surfactant, a liquid medicine that is given into the lungs to help them to breathe more effectively. The research project is comparing two different ways to give surfactant to babies that need it. Both of these methods are currently used at several UK neonatal units. We don’t know which method is better. 

What’s involved? 

Your baby will be participating in a study called a randomised controlled trial. This is because we do not know which method is better for giving surfactant treatment to babies. We will put the babies into two groups and compare the results to see if one is better: one group of babies will receive surfactant by laryngoscope and catheter, and the other group of babies will receive surfactant by supraglottic airway. To try to make sure the groups are the same, each baby is put into a group by chance (random), so there is an equal chance (like flipping a coin) for your baby to receive either treatment method. 

Other than the method of surfactant treatment, the treatment provided to babies in the research project will not be any different to standard care, and no extra tests are required. We will record health information from your baby’s medical records up until they are discharged home. We will also take a video recording of your baby receiving surfactant treatment to collect information about the two treatment methods. 

Who’s it for? 

Premature babies needing surfactant treatment (medical delivery of the natural lung liquid, surfactant, into a baby’s lungs) 

If you are interested in taking part, please contact us

Research Midwives, Kensey Team


The Generation Study

Why? 

The Generation Study is a long-term research study. We want to understand if we can improve how we diagnose and treat genetic conditions by looking at the DNA of newborn babies. 

The research has two main goals. 

  • Find rare genetic conditions early, so affected babies can get treatment fast  
  • Learn more about genes and health, so we can improve testing and treatment for genetic conditions in the future 

What’s involved? 

The NHS already offers newborn blood spot screening (the ‘heel prick’ test) to all babies when they’re 5 days old. This tests for 9 rare, treatable conditions. It’s an NHS service that has already been well-researched. The Generation Study is different from the newborn blood spot screening. This study looks for genetic changes that can cause around 200 rare conditions. 

Who’s it for? 

To be eligible for the study, you need to:  

  • Be pregnant  
  • Be 16+ years old  
  • Have an NHS number  
  • Be registered with a GP in England  
  • Not be having twins, triplets, etc.  
  • Not be a surrogate or planning to give the baby up for adoption 

If you are interested in taking part, please contact us

Research Midwives, Kensey Team


Panda

Primary prevention of maternal ANaemia to avoid preterm Delivery and other Adverse outcomes.  

Why? 

Currently, pregnant women are treated for anaemia when it shows up on a routine blood test. We (the PANDA research team) want to understand if taking iron supplements earlier in pregnancy can prevent anaemia. 

What’s involved? 

Participants are randomly allocated (like tossing a coin) to take either iron tablets or a placebo (‘dummy’ tablets) every day from when you join the study until 6 weeks after delivery.  

This is a double-blind study so neither the participants nor the team looking after you knows which group you are in. Participants will be offered reminders about taking your tablets. There will be 3 short questionnaires at 28 weeks of pregnancy and three, 5-minute questionnaires at 6 weeks after birth, all online. If participants become anaemic during the study an additional one of these questionnaires will be completed after the initial treatment.   

Participants will also be asked if you would like to take part in an interview about their experience of taking part in the PANDA study and receiving reminders to take the study tablets as recommended. This interview will take place at the end of the study.  

Who’s it for? 

Pregnant women aged 18 or over, who do not have anaemia.

If you are interested in taking part, please contact us

Research Midwives, Kensey Team


Beatrix

We are inviting pregnant women to participate in a study evaluating Group B Streptococcus (GBS) in pregnancy.

Participation includes:

  • Receiving 1 dose of the study vaccine or placebo
  • Additional monitoring following vaccination
  • A 24 hour phoneline to the study team
  • You will be compensated for your time and travel.

To find out more:

Page last reviewed: 29 April 2026

Text Size

Change font

Contrast